 The poster, entitled: Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in Hemophilia B presented by Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst Biosciences highlights results from the study. Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of 12 in all participants, with FIX levels of up to 27 and a half-life of 2.5 to 5.1 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing. 